Holen Sie sich die Stockscreener-App
0.556
1.10%
-0.0062
Handel nachbörslich:
.54
-0.016
-2.88%
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView
TradingKey - TradingKey
Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTOR|Citius Oncology Inc|Price:0.562|Chg%:-0.016 - TradingKey
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CTOR|Citius Oncology Inc|Price:0.541|Chg%:-0.037 - TradingKey
Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com UK
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - PR Newswire
Citius Oncology Inc. (CTOR) Q2 2026 Earnings: Significant EPS Miss with No Reported RevenueProfit Inflection Point - dars.gov.et
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTOR Q1 2026 Earnings: Significant EPS Miss Despite Stock RallyProfit Recovery Report - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss as Pre-Revenue Company Posts Wider Than Expected LossOne-Time Gain Impact - dars.gov.et
Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView
Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView
Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
CTOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology (CTOR) Edges Higher as Shares Approach Resistance at $0.73Volume Rate Change - dars.gov.et
Citius Oncology Inc (CTOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
CTOR Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin; No Revenue ReportedEPS Growth Rate - DonanımHaber
CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill
Citius Oncology Inc (CTOR) Institutional Confidence - TradingKey
CTOR Q1 2026 Earnings: Deep EPS Miss Highlights Pre‑Revenue ChallengesEstimate Revision Count - newsline.com
Citius Oncology Inc. (CTOR) Gains 6% as Buyers Defend Key SupportSentiment Divergence - newsline.com
Citius Oncology Inc. (CTOR) Edges Higher as Shares Test Key Resistance LevelsBox Spread - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com
Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportMcClellan Summation - newsline.com
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus
Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):